Loco-regional interventional treatment of hepatocellular carcinoma: Techniques, outcomes, and future prospects

Riccardo Lencioni, Laura Crocetti, Paolo De Simone, Franco Filipponi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Summary Loco-regional interventional treatments continue to evolve and to play a major role in the therapeutic management of hepatocellular carcinoma (HCC). Image-guided ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection is precluded. Recent refinements in technique have substantially increased the ability of radiofrequency ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and nonthermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and safety profile of TACE compared with conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.

Original languageEnglish (US)
Pages (from-to)698-703
Number of pages6
JournalTransplant International
Volume23
Issue number7
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Therapeutics
Pharmaceutical Preparations
Molecular Targeted Therapy
Standard of Care
Hot Temperature
Transplantation
Outcome Assessment (Health Care)
Clinical Trials
Safety
Recurrence

Keywords

  • Hepatocellular carcinoma
  • Image-guided ablation
  • Molecular targeted therapies
  • Transarterial chemoembolization

ASJC Scopus subject areas

  • Transplantation
  • Medicine(all)

Cite this

Loco-regional interventional treatment of hepatocellular carcinoma : Techniques, outcomes, and future prospects. / Lencioni, Riccardo; Crocetti, Laura; De Simone, Paolo; Filipponi, Franco.

In: Transplant International, Vol. 23, No. 7, 2010, p. 698-703.

Research output: Contribution to journalArticle

Lencioni, Riccardo ; Crocetti, Laura ; De Simone, Paolo ; Filipponi, Franco. / Loco-regional interventional treatment of hepatocellular carcinoma : Techniques, outcomes, and future prospects. In: Transplant International. 2010 ; Vol. 23, No. 7. pp. 698-703.
@article{7cad503f07be4535b29387ec2dc3e42b,
title = "Loco-regional interventional treatment of hepatocellular carcinoma: Techniques, outcomes, and future prospects",
abstract = "Summary Loco-regional interventional treatments continue to evolve and to play a major role in the therapeutic management of hepatocellular carcinoma (HCC). Image-guided ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection is precluded. Recent refinements in technique have substantially increased the ability of radiofrequency ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and nonthermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and safety profile of TACE compared with conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.",
keywords = "Hepatocellular carcinoma, Image-guided ablation, Molecular targeted therapies, Transarterial chemoembolization",
author = "Riccardo Lencioni and Laura Crocetti and {De Simone}, Paolo and Franco Filipponi",
year = "2010",
doi = "10.1111/j.1432-2277.2010.01109.x",
language = "English (US)",
volume = "23",
pages = "698--703",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Loco-regional interventional treatment of hepatocellular carcinoma

T2 - Techniques, outcomes, and future prospects

AU - Lencioni, Riccardo

AU - Crocetti, Laura

AU - De Simone, Paolo

AU - Filipponi, Franco

PY - 2010

Y1 - 2010

N2 - Summary Loco-regional interventional treatments continue to evolve and to play a major role in the therapeutic management of hepatocellular carcinoma (HCC). Image-guided ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection is precluded. Recent refinements in technique have substantially increased the ability of radiofrequency ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and nonthermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and safety profile of TACE compared with conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.

AB - Summary Loco-regional interventional treatments continue to evolve and to play a major role in the therapeutic management of hepatocellular carcinoma (HCC). Image-guided ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection is precluded. Recent refinements in technique have substantially increased the ability of radiofrequency ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and nonthermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and safety profile of TACE compared with conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.

KW - Hepatocellular carcinoma

KW - Image-guided ablation

KW - Molecular targeted therapies

KW - Transarterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=77953184336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953184336&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2010.01109.x

DO - 10.1111/j.1432-2277.2010.01109.x

M3 - Article

C2 - 20492618

AN - SCOPUS:77953184336

VL - 23

SP - 698

EP - 703

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 7

ER -